Exscientia Investor Presentation Deck
October 2023, 69 slides
  1. Exscientia
  2. Related Decks
  3. Investor Presentation Decks
precision designed medicine | Exscientia
forward looking statements | Exscientia
patient first integrated technologies to discover design and develop precision medicines | Exscientia
delivering better pipeline candidates faster | Exscientia
progress and upcoming milestones | Exscientia
new year collaboration leveraging driven platform | Exscientia
major reasons clinical trials fail | Exscientia
solution integrating knowledge of the patient and drug precision medicine | Exscientia
why are our clinical candidates different | Exscientia
pipeline advancing to the clinic | Exscientia
high value partnerships also create strong foundation | Exscientia
expanding technologies enhance value creation | Exscientia
our strategy maintains balance sheet strength | Exscientia
technologies | Exscientia
patient first is a learning process in ses | Exscientia
our differentiated process | Exscientia
exalt study first driven functional precision medicine platform to directly improve cancer treatment patient outcomes | Exscientia
exalt study results | Exscientia
extensive proprietary data generation capabilities | Exscientia
creating a consistent flow of high quality targets be | Exscientia
and validating targets with centaur biologist be | Exscientia
cancer is a heterogenous disease | Exscientia
precision objectives for precision design | Exscientia
data and model agnostic | Exscientia
| Exscientia
active learning leads to creative breakthroughs | Exscientia
defining patient selection during drug design | Exscientia
advancing to the clinic | Exscientia
design patient centric drugs with an improved probability of success | Exscientia
inhibitor elucidate phase ongoing | Exscientia
elucidate phase ongoing in advanced solid | Exscientia
elucidate phase ongoing in advanced solid | Exscientia
inhibition provides broad oncology opportunity | Exscientia
precision design to effectiveness | Exscientia
our candidate resolves critical design issues | Exscientia
is highly effective in classical models | Exscientia
evaluating the potential of in primary tissue | Exscientia
expanding potential efficacy with rational combinations | Exscientia
proposed of exposure | Exscientia
theta in licensed by phase study ongoing a sole | Exscientia
theta in licensed by in august | Exscientia
large failures on an attractive target nor sab properties unbound | Exscientia
our approach | Exscientia
phase to start in i at | Exscientia
enabling studies ongoing | Exscientia
highly differentiated inhibitor | Exscientia
inhibition leads to cell death | Exscientia
precision design to therapeutic window | Exscientia
delivering quality candidate against a novel | Exscientia
technology in action precision design of its | Exscientia
active learning enabled breakthrough for | Exscientia
inhibits growth in | Exscientia
benefit of reversible target engagement on platelets | Exscientia
efficacy maintained with intermittent dosing | Exscientia
| Exscientia
summary | Exscientia
malt enabling studies ongoing bloom | Exscientia
potential to avoid key class wide safety concern | Exscientia
malt inhibition of immune cell signalling | Exscientia
malt exs | Exscientia
avoiding a | Exscientia
malt competitor profiles | Exscientia
technology in action precision design of he pias | Exscientia
leveraged physics based predictive modelling | Exscientia
inhibits insensitive model growth in | Exscientia
deepens response to in | Exscientia
malt | Exscientia
summary | Exscientia
| Exscientia
See More
Exscientia
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Cancer
Inhibitor
Medicine
Precision medicine
Ovarian cancer
Clinical trial
Recent decks by Exscientia
Investor Presentation
March 2024
Results
March 2024
Investor Day
January 2024
Investor Presentation
November 2023
See all presentations by Exscientia (14 decks)
Related decks
Nuvectis Pharma
Investor Presentation
January 2024
Nuvectis Pharma
Investor Presentation
August 2023
Nuvectis Pharma
Investor Presentation
July 2023
Allarity Therapeutics
Investor Conference
September 2022
Erasca
Investor Presentation
November 2023
Erasca
Investor Presentation
August 2023
TCR2 Therapeutics
Results
September 2022
BioAtla
IPO
December 2020
Recent decks by Exscientia
See all presentations (14 decks)
Investor Presentation
March 2024
Results
March 2024
Investor Day
January 2024
Investor Presentation
November 2023
Nuvectis Pharma
Investor Presentation
January 2024
Nuvectis Pharma
Investor Presentation
August 2023
Nuvectis Pharma
Investor Presentation
July 2023
Allarity Therapeutics
Investor Conference
September 2022
Erasca
Investor Presentation
November 2023
Erasca
Investor Presentation
August 2023
TCR2 Therapeutics
Results
September 2022
BioAtla
IPO
December 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io